Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.88 USD
Change Today +0.06 / 0.88%
Volume 564.4K
AGEN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AGEN) Snapshot

Open
$6.75
Previous Close
$6.82
Day High
$6.96
Day Low
$6.70
52 Week High
06/16/15 - $10.16
52 Week Low
10/13/14 - $2.56
Market Cap
580.0M
Average Volume 10 Days
1.0M
EPS TTM
$-0.79
Shares Outstanding
84.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENUS INC (AGEN)

agenus inc (AGEN) Related Businessweek News

No Related Businessweek News Found

agenus inc (AGEN) Details

Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing heat shock protein vaccine, which is in Phase II studies for treating cancer and infectious diseases; and QS-21 Stimulon, a saponin-based vaccine adjuvant for use in pre-clinical and clinical stage vaccine programs that target prophylactic or therapeutic impact in a range of infectious diseases and cancer. Agenus Inc. also holds rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1, a glycoprotein expressed on T cell and NK cell lymphocytes. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

162 Employees
Last Reported Date: 08/3/15
Founded in 1994

agenus inc (AGEN) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $502.4K
Principal Accounting Officer and Vice Preside...
Total Annual Compensation: $222.9K
Chief Business Officer
Total Annual Compensation: $204.3K
Chief Compliance Officer, Chief Legal Officer...
Total Annual Compensation: $289.2K
Chief Scientific Officer
Total Annual Compensation: $323.8K
Compensation as of Fiscal Year 2014.

agenus inc (AGEN) Key Developments

Agenus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Agenus Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $3.377 million against $3.074 million a year ago. Operating loss was $33.195 million against $8.220 million a year ago. Net loss attributable to common stockholders was $40.461 million or $0.53 per diluted share against $7.813 million or $0.12 per diluted share a year ago. For the six months, the company reported revenue of $10.330 million against $3.795 million a year ago. Operating loss was $51.487 million against $18.323 million a year ago. Net loss attributable to common stockholders was $59.253 million or $0.83 per diluted share against $8.501 million or $0.15 per diluted share a year ago. The increase in net loss attributable to common stockholders for the six months ended June 30, 2015, compared to the net loss attributable to common stockholders for the same period in 2014, was primarily due to the advancement of the check point modulator programs, the $20.7 million non-cash expense from fair value adjustments of the contingent obligations and the $13.2 million charge for the purchase of the SECANT yeast display platform in 2015.

Agenus Inc. to Report Q2, 2015 Results on Jul 23, 2015

Agenus Inc. announced that they will report Q2, 2015 results at 11:00 AM, US Eastern Standard Time on Jul 23, 2015

Agenus Inc., Q2 2015 Earnings Call, Jul 23, 2015

Agenus Inc., Q2 2015 Earnings Call, Jul 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $6.88 USD +0.06

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies
 

Industry Analysis

AGEN

Industry Average

Valuation AGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.5x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit www.agenusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.